Investors

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
04/03/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2019, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units representing an aggregate of 30,500 shares of the company’s common stock. All of the above-described awards were made under the GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each grant... 
Printer Friendly Version
04/02/19GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019, at 10:10 a.m. British Summer Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT ... 
Printer Friendly Version
03/06/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2019, the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 76,100 shares of the company’s common stock with a per share exercise price of $53.48 and restricted stock units for an aggregate of 76,850 shares of the company’s common stock. All of the above-described awards were made under... 
Printer Friendly Version
03/04/19GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11, 2019, at 4:50 p.m. Eastern Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT is ... 
Printer Friendly Version
02/27/19GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2018. “Last year was successful for GBT as we achieved several important clinical and regulato... 
Printer Friendly Version
02/21/19GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Thursday, February 28, 2019, at 1 p.m. Eastern Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT i... 
Printer Friendly Version
02/19/19GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease
—The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle Cell Disease— —GBT Will Fund Proposals With the Highest Potential to Impact Patient Care— SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the launch of the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) to prov... 
Printer Friendly Version
02/05/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 21,850 shares of the company’s common stock with a per share exercise price of $48.44 and restricted stock units for an aggregate of 39,025 shares of the company’s common stock. All of the above-described awards were made und... 
Printer Friendly Version
01/29/19GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
—Company Plans to Submit NDA for Voxelotor Under FDA Accelerated Approval Pathway Later This Year— SOUTH SAN FRANCISCO, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell disease (SCD) were published online in Blood, a peer-reviewed publication of the American Society of Hematology. Voxelotor is being developed as a potentially disease-modifying therapy for ... 
Printer Friendly Version
01/03/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on January 1, 2019, the compensation committee of the Company’s board of directors granted three new employees options to purchase an aggregate of 6,000 shares of the Company’s common stock with a per share exercise price of $41.05 and restricted stock units for an aggregate of 3,950 shares of the Company’s common stock. All of the above-descri... 
Printer Friendly Version
01/02/19GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 11:30 a.m. Pacific Time. The presentation and Q&A session will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GB... 
Printer Friendly Version